An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)

NCT01806298 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

78

Enrollment

INDUSTRY

Sponsor class

Conditions

Adult Growth Hormone Deficiency

Interventions

DRUG: Saizen® solution for injection (referred as Saizen®)

Sponsor

Merck KGaA, Darmstadt, Germany